Comparative Pharmacology
Head-to-head clinical analysis: DIUCARDIN versus INDERIDE 80 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUCARDIN versus INDERIDE 80 25.
DIUCARDIN vs INDERIDE-80/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Hydrochlorothiazide 25-50 mg orally once daily, titrated based on response. Maximum dose 100 mg/day.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 18-24 hours in normal renal function. This prolongs significantly in renal impairment, requiring dose adjustment.
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Primarily renal excretion: approximately 60-70% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination accounts for about 20-30%, with some enterohepatic circulation.
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Category C
Category C
Thiazide Diuretic
Beta Blocker and Thiazide Diuretic